Clinical Trial Update: A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma after definitive chemoradiotherapy; status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING